Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-08-10. The firm is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The firm researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
最新の財務諸表(Form-10K)によると、Clearmind Medicine Incの総資産は$0で、純損失は$-3です。
CMNDの主要な財務比率は何ですか?
Clearmind Medicine Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Clearmind Medicine Incの収益はセグメントまたは地域別にどのように分けられていますか?
Clearmind Medicine Inc の最大収益セグメントは Cars and Spare Parts で、最新の利益発表における収益は 6,005,243,000 です。地域別に見ると、Italy が Clearmind Medicine Inc の主要市場であり、収益は 527,727,000 です。